BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 2nd Quarter - Amendment

AQUESTIVE THERAPEUTICS, INC

via RUBICON ADVISORS, LLC

2nd Quarter (Apr 1 - June 30) · 2022Posted Jul 21, 2022Filing document ↗LDA record ↗

Income$45Kfee reported

Client

Name: AQUESTIVE THERAPEUTICS, INC
Description: Pharmaceutical
Location: New Jersey · United States of America

Registrant

Firm: RUBICON ADVISORS, LLC
Description: Lobbying firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Pharmacy
H.R, 1629/S 250: Fairness in Orphan Drug Exclusivity Act
LobbyistsWILLIAM BURKE
TargetedFood & Drug Administration (FDA)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

AQUESTIVE THERAPEUTICS, INC — Lobbying — Receipts Report